We introduce the process of finding key targets for primary cancers using our AI technologies such as Wx and DearTRANS.
Read More
고형암 유발 DDT2 전사인자 선택적 제거 혁신 신약 개발
디어젠의 인공지능 기술을 통해, 고형암을 유발하는 핵심 신규 타깃을 찾고 이에 따른 신약후보물질을 도출하는 과정을 소개합니다.
A new state of the art drug target interaction model, Molecule Transformer based Drug Target Interaction (MT-DTI) Model.
Deargen Presented a world-class drug-protein interaction prediction model, MT-DTI (Molecule Transformer Drug Target Interaction Model). This research is published in the Journal of Machine Learning Research (JMLR).
Read More
MT-DTI, 세계 최고 성능의 ‘약물-단백질 상호작용 예측’ 모델
디어젠(주)는 세계 최고 수준의 약물-단백질 상호작용 예측 모델 MT-DTI 대해서 발표했습니다. 연구 결과는 JMLR(Journal of Machine Learning Research)저널에 게재되어 있습니다.
Read More
[Press Release] Deargen, Unveil the performance Results of a New Drug-Protein Interaction Prediction Model.
Deargen Inc. Presented at MLHC 2019, “All 8 FDA-approved EGFR anticancer drugs were predicted using a database of ninety-seven million chemical compounds”.
Read More
[보도자료] 디어젠(주), ‘약물-단백질 상호작용 예측’ AI 모델 연구 성과 발표
인공지능(AI)기반 신약발굴 및 플랫폼 개발 전문기업 디어젠(주)(대표이사 강길수)은 Self-Attention 메커니즘을 기반으로 한 약물-단백질 상호작용 예측 알고리즘(MT-DTI, Molecule Transformer Drug Target Interaction) 개발 성과를 2019년 8월 8일부터 10일까지 진행되는 MLHC(Machine Learning for Healthcare)2019 학회에서 발표했다.
Read More
Treatment of Sarcopenia using Small Molecules
Sarcopenia is a new type of age-related disease that has been newly classified as a disease since October 2016. It is defined as a disease with a reduction in skeletal muscle mass as aging progresses and there are no treatments for age-related sarcopenia that have been approved by the FDA so far. In this regard, Deargen is challenging the development of treatments for sarcopenia using small molecules.
Read More
Undruggable to Degradable with AI
PROTAC is known as a new platform for disease treatment that has been difficult to reach with existing biopharmaceuticals. Deargen is accelerating the development of drugs through PROTAC by rapidly and precisely searching for small molecules that can bind to the target protein.
Read More
Colorectal Cancer, MERTK, and Small molecular
The study of colorectal cancer has shown that MERTK (TYRO3 / AXL / MER, TAM receptor kinase family) is an important target for cancer cell immune response evasion mechanism. Thus, Deargen is researching by focusing on small molecule inhibitors.
Read More
ALS (Lou Gehrig), a Challenge to Radical Cure
ALS treatments that currently are being used under FDA approval have a level that relieves symptoms and slows the progression of Lou Gehrig. Deargen is challenging the development of new ALS treatments by reducing TDP-43 protein aggregation observed in more than 90% of patients with Lou Gehrig.
Read More